Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Intranasal 2-DG in Healthy Volunteers
NCT05314933Phase 1Completed
- Sponsor
- G.ST Antivirals
- Start
- Mar 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute nasopharyngitis comparing 2-Deoxy-D-glucose with Placebo (2 arms). Primary endpoint: Adverse drug reactions (ADRs) at 168 hours. Started Mar 2022; status: completed.
02
Drugs
2-deoxy-d-glucose
03
Conditions
acute nasopharyngitis
Beyond the preview
Go deeper on NCT05314933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314933.